secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2021-09-17T23:59:59+00:00
Accession:  0001438533-21-000045
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics appoints Sandra Calvin as Chief Accounting Officer effective Sept 15, 2021
--------------------------------------------------------------------------------

- Sandra Calvin, 56, appointed Vice President, Corporate Controller and Chief Accounting Officer.
- Calvin has served as VP, Corporate Controller since April 2018; joined the company in 2014.
- Laura Clague remains CFO and principal financial officer; Calvin assumes principal accounting officer duties.
- Calvin is a CPA (inactive) with prior roles at Amylin Pharmaceuticals and Vical Incorporated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/0001438533-21-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/tvtx-20210914.htm
  HTML page:      https://secwatch.observer/filing/0001438533-21-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer